^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IPH6501

    i
    Other names: IPH6501, NKCE4, tetra-specific ANKET molecule, IPH65
    Company:
    Innate
    Drug class:
    CD20 inhibitor, NK cell stimulant
    Related drugs:
    2ms
    Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=184, Recruiting, Innate Pharma | Not yet recruiting --> Recruiting | Initiation date: Oct 2023 --> Mar 2024
    Enrollment open • Trial initiation date
    |
    IPH6501
    12ms
    IPH6501 IS A FIRST-IN-CLASS TETRASPECIFIC ANTIBODY-BASED NATURAL KILLER CELL ENGAGER THERAPEUTIC DEVELOPED FOR THE TREATMENT OF B-CELL NON-HODGKIN'S LYMPHOMAS (EHA 2023)
    Despite several generations of CD20-targeting drugs including rituximab, ofatumumab, and obinutuzumab, and more recent approvals of new CD20-targeting agents, innovative strategies are still needed for B-NHL patients who relapse or are refractory (R/R) after multiple lines of treatment. Our preclinical data showed that IPH6501, a CD20-targeting tetraspecific antibody-based NK cell engager therapeutic, could be a powerful first-in-class new asset to harness the anti-tumor functions of NK cells in CD20 +B-cell malignancies. IPH6501 is expected to enter FIH clinical study in 2023. 1.
    IO biomarker
    |
    IL2RA (Interleukin 2 receptor, alpha) • FCGR3A (Fc Fragment Of IgG Receptor IIIa)
    |
    CD19 positive • CD20 expression • IL2RA expression
    |
    Rituxan (rituximab) • Gazyva (obinutuzumab) • IPH6501